NAECB Asthma Medication 3

Question 1

A pregnant patient in her third trimester has moderate persistent asthma. Which ICS is considered the preferred agent due to the most safety data in pregnancy?

Accepted Answer

Budesonide

Answer

Budesonide has the most human pregnancy safety data and is the preferred ICS during pregnancy per NAEPP guidelines.

Question 2

Which adverse effect is MOST associated with long-term systemic corticosteroid use in pediatric asthma patients?

Accepted Answer

Growth suppression

Answer

Long-term systemic corticosteroids in children can suppress the hypothalamic-pituitary axis and impair linear growth.

Question 3

Dupilumab (Dupixent) targets which cytokine pathway making it effective in eosinophilic and type 2 asthma?

Accepted Answer

IL-4/IL-13 via IL-4Rα blockade

Answer

Dupilumab blocks IL-4Rα, inhibiting both IL-4 and IL-13 signaling, key drivers of type 2 inflammation.

Question 4

When stepping DOWN asthma therapy per GINA/NAEPP guidelines, what minimum period of symptom control should be achieved before reducing medication?

Accepted Answer

3 months

Answer

GINA recommends at least 3 months of good asthma control before considering step-down of controller therapy.

Question 5

A patient takes salmeterol (Serevent) as monotherapy without an ICS. What is the primary safety concern?

Accepted Answer

Increased risk of asthma-related death (black box warning)

Answer

LABA monotherapy (without ICS) carries an FDA black box warning for increased risk of asthma-related death.

NAECB Exam Practice Test

NAECB Exam Practice Test

NAECB Asthma Medication 3